New trials, publications, preprints and grants on this target, month by month.
Trial
Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
15 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
FLT3-ITD Targeted Therapy in Fit AML Patients
1 Dec 2026· PHASE2_PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
11 Nov 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
Performance Evaluation and Validation of a Next-Generation Sequencing-Based Measurable Residual Disease Assay for FLT3 Internal Tandem Duplication Detection in Acute Myeloid Leukemia.
6 Nov 2026· Annals of laboratory medicine· PUBMED
Publication
Frequent FLT3 and IDH co-mutations in acute myeloid leukemia with mutated NPM1, NUP98 rearrangement, and KMT2A partial tandem duplication but not rearrangement: potential for combined targeted therapy.
5 Nov 2026· Haematologica· PUBMED
Publication
Synthesis, in silico studies, and in vitro evaluation of novel isoindigo inhibitors targeting wild-type and D835Y mutant FLT3.
3 Nov 2026· RSC advances· PUBMED
Trial
MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC )
1 Nov 2026· NA · NOT_YET_RECRUITING· CTGOV
Trial
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Prognostic Impact of FLT3-ITD Microclones in AML: An EHA AML-Specialized Working Group Study.
1 Nov 2026· American journal of hematology· PUBMED
Publication
Clinical and molecular characteristics of FLT3-ITD microclones in elderly patients with acute myeloid leukemia receiving less-intensive therapy.
30 Oct 2026· Leukemia· PUBMED
Publication
Quizartinib in older patients (aged ≥60 years) with newly diagnosed FLT3-ITDpositive acute myeloid leukemia: subgroup analyses from QuANTUM-First.
29 Oct 2026· Haematologica· PUBMED
Publication
Prognostic Impact of FLT3-ITD Allelic Ratio in AML Patients Treated With High-Dose Anthracycline and a FLT3 Inhibitor.
26 Oct 2026· American journal of hematology· PUBMED
Publication
Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML.
23 Oct 2026· Annals of hematology· PUBMED
Publication
Targeting the mitochondrial complex I subunit NDUFS2 potentiates FLT3 inhibition in acute myeloid leukaemia with FLT3 internal tandem duplication.
19 Oct 2026· Leukemia· PUBMED
Publication
Focus on Azole-Based and Other N-Containing Heterocycles Within the Landscape of Current Structural Classes as Feline McDonough Sarcoma-Like Tyrosine Kinase 3 (FLT3) Inhibitors for Acute Myeloid Leukemia.
19 Oct 2026· Medicinal research reviews· PUBMED
Publication
XY0206: A promising sunitinib-derived FLT3 inhibitor targeting therapy-resistant acute myeloid leukemia.
15 Oct 2026· The Journal of clinical investigation· PUBMED
Publication
Successful Salvage Therapy With Quizartinib Plus Chemotherapy Followed by Quizartinib Monotherapy for Transplant Bridging and Post-Transplant Maintenance in a Child With Induction-Refractory FLT3-ITD-Positive AML.
15 Oct 2026· Pediatric blood & cancer· PUBMED
Publication
Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML.
13 Oct 2026· Blood advances· PUBMED
Publication
Genomic Determinants of Induction Failure and Persistent Prognostic Risk of FLT3-ITD in Pediatric Acute Myeloid Leukemia.
12 Oct 2026· Cancers· PUBMED
Publication
Structure-Based Optimization of 2-Aminopyrimidine Derivatives as Potent Multi-target FLT3/CHK1/IRAK4 Inhibitors for Acute Myeloid Leukemia.
8 Oct 2026· Journal of medicinal chemistry· PUBMED
Publication
HPMES: an ultra-sensitive mutation enrichment strategy for FLT3-ITD MRD monitoring in acute myeloid leukemia.
7 Oct 2026· Biosensors & bioelectronics· PUBMED
Publication
FLT3-Mutated AML: Transplanting with Precision in the Targeted Era.
1 Oct 2026· Current hematologic malignancy reports· PUBMED
Publication
Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy.
29 Sept 2026· Journal of clinical medicine· PUBMED
Publication
Novel juxtamembrane FLT3 in-frame insertion in a child with refractory AML: a case report of durable remission following allogeneic HSCT and FLT3 inhibitor therapy.
25 Sept 2026· Frontiers in oncology· PUBMED
Publication
Sorafenib enhances graft-versus-leukemia activity through IL-18-mediated macrophage and NK cell crosstalk in FLT3-ITD acute myeloid leukemia.
22 Sept 2026· Cell reports· PUBMED
Publication
Chromosomal Heterogeneity and Enrichment of Mitotic Regulatory Programs Reveal a Therapeutic Vulnerability in Cytarabine-Resistant FLT3-ITD AML.
21 Sept 2026· Current issues in molecular biology· PUBMED
Publication
FLT3 inhibitor maintenance after allogeneic transplantation is associated with improved survival in FLT3-mutated AML: MRD-stratified evidence from an updated meta-analysis.
21 Sept 2026· Bone marrow transplantation· PUBMED
Publication
Design, synthesis and biological evaluation of a series of new, potent FLT3 PROTAC degraders with rigid linkers.
19 Sept 2026· Bioorganic & medicinal chemistry· PUBMED
Publication
RAS seals fate in AML besieged by FLT3 and BCL2 inhibitors.
17 Sept 2026· Blood· PUBMED
Publication
Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.
17 Sept 2026· Blood· PUBMED